Malaz Boustani, MD, MPH; Britt Peterson, MD, MPH; Laura Hanson, MD, MPH; Russell Harris, MD, MPH; Kathleen N. Lohr, PhD
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the U.S. Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank their liaisons from the U.S. Preventive Services Task ForceCynthia Mulrow, MD, MSc, The University of Texas Health Science Center, San Antonio, Texas, and Albert Siu, MD, MSPH, Mount Sinai Medical Center, New York, New Yorkfor their assistance with the full systematic evidence review. They also thank David Atkins, MD, MPH, Director, Agency for Healthcare Research and Quality Clinical Prevention Program, for his advice and counsel and Sonya Sutton, BSPH, and Loraine Monroe (both of RTI) and Carol Krasnov and Audrina Bunton (both of the University of North Carolina) for their assistance.
Grant Support: This study was conducted by the RTIUniversity of North Carolina Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality, Rockville, Maryland (contract no. 290-97-0011, task order 3). Dr. Boustani has received career development support from the Program on Aging, John A. Hartford Foundation, and the American Federation for Aging Research.
Potential Financial Conflicts of Interest:Grants received: M. Boustani (Pfizer, Inc.).
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (www.ahrq.gov/clinic/uspstfix.htm) or in print by subscribing to the Guide to Clinical Preventive Services, Third Edition: Periodic Updates. The cost of this subscription is $60, and it can be ordered through the Agency for Healthcare Research and Quality Publications Clearinghouse (phone, 800-358-9295; e-mail, firstname.lastname@example.org).
Current Author Addresses: Dr. Boustani: Regenstrief Institute, Inc., 1050 Wishard Boulevard, RG 6, Indianapolis, IN 46202-2872.
Dr. Peterson: University of North Carolina at Chapel Hill, 706C Hibbard Drive, Chapel Hill, NC 27514.
Dr. Hanson: University of North Carolina at Chapel Hill, 258 Macnider, CB #7110, Chapel Hill, NC 27599.
Dr. Harris: Sheps Center for Health Services Research, 725 Airport Road, CB #7590, Chapel Hill, NC 27599-2949.
Dr. Lohr: RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709.
Dementia is a large and growing problem but is often not diagnosed in its earlier stages. Screening and earlier treatment could reduce the burden of suffering of this syndrome.
To review the evidence of benefits and harms of screening for and earlier treatment of dementia.
MEDLINE, PsycINFO, EMBASE, the Cochrane Library, experts, and bibliographies of reviews.
The authors developed eight key questions representing a logical chain between screening and improved health outcomes, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources.
Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to U.S. Preventive Services Task Force criteria.
No randomized, controlled trial of screening for dementia has been completed. Brief screening tools can detect some persons with early dementia (positive predictive value 50%). Six to 12 months of treatment with cholinesterase inhibitors modestly slows the decline of cognitive and global clinical change scores in some patients with mild to moderate Alzheimer disease. Function is minimally affected, and fewer than 20% of patients stop taking cholinesterase inhibitors because of side effects. Only limited evidence indicates that any other pharmacologic or nonpharmacologic intervention slows decline in persons with early dementia. Although intensive multicomponent caregiver interventions may delay nursing home placement of patients who have caregivers, the relevance of this finding for persons who do not yet have caregivers is uncertain. Other potential benefits and harms of screening have not been studied.
Screening tests can detect undiagnosed dementia. In persons with mild to moderate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slowing cognitive decline. The effect of cholinesterase inhibitors or other treatments on persons with dementia detected by screening is uncertain.
Table 1. Key Questions, Eligibility Criteria, and Number of Articles Meeting Criteria
Table 2. Estimates of Undiagnosed Dementia in Primary Care Practices
Table 3. Accuracy of Screening Tests for Dementia
Table 4. Efficacy of Cholinesterase Inhibitors in Patients with Alzheimer Disease after 3 to 12 Months
Table 5. Summary of Efficacy of Caregiver Interventions
Appendix Table 1. Key Questions for Screening for Dementia Syndrome
Analytic framework for screening for dementia.
Appendix Table 2. Dementia Syndrome: Eligibility Criteria, Search Strategy, and Results of Searches
Selection of articles for key question 1: direct evidence.
Selecting articles for key question 2: prevalence of undiagnosed dementia.
Selecting articles for key question 3: accuracy of screening tests.
Selecting articles for key question 4: efficacy of pharmacologic treatment.
Selecting articles for key question 5: efficacy of nonpharmacologic treatment.
Selecting articles for key question 6: interventions for planning.
Selecting articles for key questions 7 and 8: harms of screening and treatment.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Malaz Boustani, Britt Peterson, Laura Hanson, Russell Harris, Kathleen N. Lohr. Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138:927–937. doi: 10.7326/0003-4819-138-11-200306030-00015
Download citation file:
Published: Ann Intern Med. 2003;138(11):927-937.
Dementia, Guidelines, Neurology, Prevention/Screening.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use